SAN FRANCISCO and BOSTON — August 11, 2025 — Leads & Copy — Apogee Therapeutics, Inc. (Nasdaq: APGE) has announced positive results from its APEX Phase 2 Part A trial, where APG777 met all primary and key secondary endpoints for treating moderate-to-severe atopic dermatitis.
The trial showed significant improvement with 3- or 6-month maintenance dosing, a notable advancement over the standard bi-weekly treatment. The company anticipates a 52-week readout in the first half of 2026. Driven by strong patient enrollment, the readout for APEX Phase 2 Part B of APG777 has been accelerated to mid-2026. The first patient has been dosed in a Phase 1b head-to-head trial of APG279 versus DUPIXENT, with results expected in the second half of 2026. Apogee’s cash, cash equivalents, and marketable securities total $621.2 million, supporting operations into Q1 2028.
Michael Henderson, M.D., CEO of Apogee, highlighted the strong execution across the pipeline and the potential of APG777 to reduce the burden of injections for patients. Carl Dambkowski, M.D., CMO of Apogee, noted the enthusiasm from patients and physicians, reinforcing confidence in APG777’s potential.
Key milestones include the ongoing Phase 1b trial of APG777 in asthma and the planned Phase 2b trials in asthma and eosinophilic esophagitis (EoE). A Phase 1 trial of APG333 in healthy volunteers is underway, with data expected in the fourth quarter of 2025.
Second quarter 2025 financial results indicate research and development expenses of $55.7 million and general and administrative expenses of $17.5 million, with a net loss of $66.1 million.
Noel Kurdi, VP, Investor Relations, Apogee Therapeutics, Inc., Noel.Kurdi@apogeetherapeutics.com
Dan Budwick, 1AB Media, dan@1abmedia.com
Source: Apogee Therapeutics
